A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(11 sites)

United States

Tufts Medical Center (Data Collection Only), Boston, Massachusetts

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack, New York

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York

Weill Cornell Medical Center (Data Collection Only), New York, New York

Mount Sinai Hospital (Data Collection Only), New York, New York

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

University of North Carolina (Data Collection Only), Chapel Hill, North Carolina